GTF2H5

Across TCGA pan-cancer cohorts, GTF2H5 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GTF2H5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GTF2H5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GTF2H5 is over-expressed in tumor.

CCRCC, HNSC, and PDAC are the cancer types where GTF2H5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GTF2H5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.254	<.001	8	view →
HNSC	All	II,III,IV	+0.192	.002	7	view →
PDAC	Female	All	+0.759	<.001	5	view →
LSCC	All	All	+0.164	<.001	5	view →
LUAD	All	All	+0.132	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GTF2H5–CCRCC

Open the CCRCC breakdown →